HomeCompareUSCMF vs ABBV

USCMF vs ABBV: Dividend Comparison 2026

USCMF yields 1230.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 USCMF wins by $117168278.82M in total portfolio value
10 years
USCMF
USCMF
● Live price
1230.01%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$117168278.92M
Annual income
$101,013,284,413,450.45
Full USCMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — USCMF vs ABBV

📍 USCMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUSCMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, USCMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
USCMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USCMF
Annual income on $10K today (after 15% tax)
$104,551.05/yr
After 10yr DRIP, annual income (after tax)
$85,861,291,751,432.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, USCMF beats the other by $85,861,291,730,376.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USCMF + ABBV for your $10,000?

USCMF: 50%ABBV: 50%
100% ABBV50/50100% USCMF
Portfolio after 10yr
$58584139.51M
Annual income
$50,506,642,219,111.11/yr
Blended yield
86.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

USCMF
No analyst data
Altman Z
-135.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USCMF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUSCMFABBV
Forward yield1230.01%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$117168278.92M$102.3K
Annual income after 10y$101,013,284,413,450.45$24,771.77
Total dividends collected$115966496.30M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: USCMF vs ABBV ($10,000, DRIP)

YearUSCMF PortfolioUSCMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$133,701$123,001.23$11,550$430.00+$122.2KUSCMF
2$1,680,015$1,536,954.74$13,472$627.96+$1.67MUSCMF
3$19,846,696$18,049,080.15$15,906$926.08+$19.83MUSCMF
4$220,507,995$199,272,029.82$19,071$1,382.55+$220.49MUSCMF
5$2,305,125,516$2,069,181,961.47$23,302$2,095.81+$2305.10MUSCMF
6$22,682,014,866$20,215,530,563.70$29,150$3,237.93+$22681.99MUSCMF
7$210,173,620,928$185,903,865,021.86$37,536$5,121.41+$210173.58MUSCMF
8$1,834,794,362,142$1,609,908,587,748.95$50,079$8,338.38+$1834794.31MUSCMF
9$15,098,125,708,837$13,134,895,741,344.69$69,753$14,065.80+$15098125.64MUSCMF
10$117,168,278,921,906$101,013,284,413,450.45$102,337$24,771.77+$117168278.82MUSCMF

USCMF vs ABBV: Complete Analysis 2026

USCMFStock

US Critical Metals Corp. engages in the acquisition, exploration, and development of resource properties. It holds an option to acquire 100% interests in Haynes cobalt project that covers a total area of approximately 192 hectares located in the Blackbird Mining District of the Idaho Cobalt Belt in Idaho; and the Clayton Ridge lithium project, which covers a total area of approximately 712.25 hectares located in Esmeralda County, Nevada. The company is based in Vancouver, Canada.

Full USCMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this USCMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USCMF vs SCHDUSCMF vs JEPIUSCMF vs OUSCMF vs KOUSCMF vs MAINUSCMF vs JNJUSCMF vs MRKUSCMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.